Type: Multi-Center Trial
Purpose: ACRC network is evaluating measurements of asthma symptoms and its impact on quality of life for people with who have a BMI of 30 or more. This population tends to have poor asthma control that does not respond well to usual asthma treatments.
Dates: May 1, 2017 - April 30, 2020
The Asthma BMI Baseline Study (ABBS) will measure the symptoms, which might limit the use of certain types of drugs and assess if participants would qualify for future clinical trials. Measures will include questionnaires, breathing tests, and an optional blood draw. ABBS is a 4 week, 2-visit study, looking for men and women age 18 or older with poorly controlled asthma to enroll.
In addition, a small trial, the Trial of Roflumilast in Asthma Management (TRIM), is being done at five ALA ACRC clinical centers: Duke Asthma Allergy Airway Center (North Carolina), Icahn School of Medicine, Mount Sinai National Jewish Health Respiratory Institute (New York), Northwestern Airways Disease Center (Illinois), Airways Disease Center the University of Arizona (Arizona), and the Vermont Lung Center (Vermont). TRIM will look at how well tolerated roflumilast is and if roflumilast improves asthma control. Results of ABBS and TRIM will be used to develop a full-scale trial using new drugs or other types of interventions that are helpful for treating asthma in this population.
If you would like to participate in this trial, please contact the participating center nearest you at the link below.
Page last updated: March 10, 2020